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Abstract 
Amitriptyline, administered orally, is currently one of the treatment options for the management of neuropathic pain and 
migraine. Because of the physicochemical properties of the molecule, amitriptyline is also a promising candidate for delivery 
as a topical analgesic. Here we report the dermal delivery of amitriptyline from a range of simple formulations. The first stage 
of the work required the conversion of amitriptyline hydrochloride to the free base form as confirmed by nuclear magnetic 
resonance (NMR). Distribution coefficient values were measured at pH 6, 6.5, 7, and 7.4. Solubility and stability of amitripty-
line were assessed prior to conducting in vitro permeation and mass balance studies. The compound demonstrated instability 
in phosphate-buffered saline (PBS) dependent on pH. Volatile formulations comprising of isopropyl alcohol (IPA) and iso-
propyl myristate (IPM) or propylene glycol (PG) were evaluated in porcine skin under finite dose conditions. Compared with 
neat IPM, the IPM:IPA vehicles promoted 8-fold and 5-fold increases in the amount of amitriptyline that permeated at 24 h. 
Formulations containing PG also appear to be promising vehicles for dermal delivery of amitriptyline, typically delivering 
higher amounts of amitriptyline than the IPM:IPA vehicles. The results reported here suggest that further optimization of 
topical amitriptyline formulations should be pursued towards development of a product for clinical investigational studies.
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Introduction
Amitriptyline is a dibenzocycloheptene-derivative tricy-
clic antidepressant (TCA) which also has potent analgesic 
effects. Oral amitriptyline is currently used to treat neuro-
pathic pain [1–3]. Amitriptyline inhibits norepinephrine and 
serotonin reuptake [4] and blocks many peripheral recep-
tors, including alpha adrenergic, muscarinic, histaminergic, 
nicotinic, and NMDA receptors [5–8]. The antinociceptive 
mechanism of action of amitriptyline also involves adeno-
sine and opioid receptors [9, 10]. In addition, in vitro and 
in vivo studies show that amitriptyline is a more potent volt-
age-gated sodium channel blocker in peripheral nerves with 
a longer duration of analgesia compared with bupivacaine 
[11, 12]. The combination of these actions may contribute 
to the peripheral efficacy of amitriptyline [13, 14].
Topical amitriptyline at various concentrations has been 
studied in clinical trials, and its efficacy has been reviewed 
by Casale et al. [15]. Some controlled clinical trials have 
also evaluated the combination of amitriptyline with other 
drugs in topical formulations. The combination of topi-
cal amitriptyline and ketamine is one of the most popular 
investigational treatments for neuropathic pain. AmiKet™ 
(EpiCept Corporation, USA) is a cream containing ami-
triptyline 4% and ketamine 2%. It has completed phase 1 
and 2 clinical trials. The outcomes of three phase 2 clinical 
trials involving 945 patients with post-herpetic neuralgia 
or diabetic painful neuropathy were reviewed in detail by 
Sawynok and Zinger [16]. The analgesic effect was reported as 
concentration-related. These trials showed the efficacy of 
AmiKet (4% amitriptyline plus 2% ketamine) for patients 
with post-herpetic neuralgia and diabetic painful neuropa-
thy. Barton et al. [17] also reported a double-blind, rand-
omized, placebo-controlled trial enrolling 203 patients with 
chemotherapy-induced peripheral neuropathy. Patients were 
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instructed to apply 1.31 g pluronic lecithin organogel gel 
containing 10 mg baclofen, 40 mg amitriptyline hydrochlo-
ride, and 20 mg ketamine hydrochloride to the area of pain. 
The results suggested a good improvement in both the sen-
sory subscale (p = 0.053) and motor neuropathy subscale 
(p = 0.021) and a slight improvement in the autonomic sub-
scale (p = 0.580) compared with a placebo.
Although topical amitriptyline has been widely studied in 
clinical trials, there is limited information in the literature 
concerning the skin absorption of amitriptyline. Stott et al. 
[18] investigated the in vitro permeation of amitriptyline 
in human skin using complex coacervation as a penetra-
tion enhancement method. The skin flux from an amitrip-
tyline: sodium deoxycholate coacervate was reported as 
6.6 ± 0.71 μg/cm2/h, which was 2.2-fold higher than the 
flux from a control solution. However, the authors did not 
disclose the formulation doses applied in the study. More 
recently, Liu et al. [19] conducted in vitro permeation studies 
in porcine skin under infinite dose conditions (0.5 mL/0.785 
 cm2) to evaluate the permeation of amitriptyline from a 
15 mM amitriptyline suspension in a 20% propylene gly-
col (PG)/pH 7.4 buffer vehicle. The formulation delivered 
14.27 ± 1.56% of amitriptyline through porcine skin after 
24 h.
Volatile formulations have previously been explored as a 
strategy to enhance skin delivery of actives. Oliveira et al. 
[20] reported the effects of ethanol on methyl paraben per-
meation across silicone membrane and human skin under 
finite dose conditions. The presence of ethanol in Transc-
utol P® (TC), dimethyl isosorbide, and isopropyl myristate 
(IPM) formulations led to increases in the percentage of 
applied methyl paraben that permeated through human skin. 
Santos et al. [21] reported finite dose permeation studies for 
fentanyl in human skin. Formulations containing IPM and 
ethanol at different degrees of drug saturation (DS) were 
tested, and results confirmed that increasing DS promoted 
fentanyl permeation. IPM is one of the most commonly 
used fatty acid esters in dermal preparations. PG, a safe and 
effective solvent for dermal delivery, is also widely used 
in topical and transdermal formulations. Additionally, the 
efficacy of PG for delivery of analgesics such as fentanyl and 
methadone has been reported previously [22, 23]. Therefore, 
in the present work, we aimed to investigate skin delivery 
of amitriptyline from formulations comprising isopropyl 
alcohol (IPA) combined with PG or IPM. A concentration 
of 4% w/v amitriptyline base solutions was chosen because 
this is within the range of 1–10% for topical amitriptyline 
formulations that were previously used in clinical studies 
[15, 24]. The concentration is also in line with AmiKet™ 
(4% amitriptyline plus 2% ketamine) [16]. A number of 
other solvents commonly used in dermal delivery were also 
evaluated for their compatibility with amitriptyline. Studies 
were conducted under finite dose conditions in porcine skin. 
As the unionized form of a drug (free acid or free base) is gen-
erally preferable for topical and transdermal delivery [25, 26], 
the free base form of the drug was used for permeation studies.
Materials and methods
Materials
Amitriptyline hydrochloride (AMI-HCl), Brij™ O20, 
dichloromethane (DCM), anhydrous acetone, and sodium 
carbonate were obtained from Sigma-Aldrich (UK). Sodium 
dihydrogen phosphate, sodium hydrogen phosphate, mag-
nesium sulphate, and dithiothreitol (DTT) were supplied 
by Fisher Scientific (UK). Phosphate-buffered saline (pH 
7.3 ± 0.2 at 25 °C) was prepared using Dulbecco A tablets 
supplied by Oxoid (UK). Octyl salicylate (OSAL), PG, IPM, 
IPA, and 1-octanol were obtained from Sigma-Aldrich (UK). 
High-performance liquid chromatography (HPLC) grade 
water, HPLC grade acetonitrile, HPLC grade methanol, 
liquid chromatography/mass spectrometry (LC-MS) grade 
acetonitrile, LC-MS grade 0.1% trifluoroacetic acid (TFA) 
solution, limonene (LIM), ethyl acetate (EtAc), and TFA 
were supplied by Fisher Scientific (UK). Chloroform-d 
 (CDCl3) were obtained from Cambridge Isotope Laborato-
ries Inc. (UK). Propylene glycol monolaurate (PGML) Type 
II and TC were gifts from Gattefossé (St. Priest, France). 
All chemicals, unless otherwise stated, were ≥ 99% purity.
Preparation of amitriptyline base
The method for the preparation of amitriptyline free base 
was developed in-house. About 30 mL of HPLC grade water 
was added to dissolve 3.14 g of amitriptyline hydrochloride 
(0.01 mol). The pH of the reaction solution was adjusted to 
9–10 with 0.5 mol/L sodium carbonate solution to convert 
amitriptyline hydrochloride to amitriptyline free base. About 
50 mL of dichloromethane was then added to extract ami-
triptyline free base. The reaction solution was allowed to 
equilibrate by stirring at 25 °C for 60 min. Subsequently, the 
organic layer was separated and the aqueous layer washed 
three times with dichloromethane (3 × 50 mL). The organic 
layers were collected together and dried with magnesium 
sulphate. Dichloromethane was removed by using a rotary 
evaporator (Heidolph, UK) and placed on a high vacuum 
line for five hours. Amitriptyline free base (2.65 g) was 
obtained as a thick oil with a yield of 95 ± 2%. Molecular 
characterization was performed by proton nuclear magnetic 
resonance (1H NMR) spectroscopy to confirm the struc-
ture. The spectrum was obtained in chloroform-d using a 
Bruker Avance 500 MHz NMR spectrometer (Bruker Cor-
poration, USA) and processed using MestReNova 11.0.4 
(Mestrelab Research, Spain). The NMR spectral signals are 
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as follows: 1H NMR (500 MHz, Chloroform-d) δ 7.34–7.30 
(m, 1H), 7.26–7.13 (m, 7H), 7.08–7.05 (m, 1H), 5.91 (t, 
1H), 3.52–3.22 (m, 2H), 2.90 (d, 2H), 2.46–2.28 (m, 4H), 
2.20 (s, 6H).
HPLC and LC‑MS analysis
The HPLC system used in this study consisted of an Agi-
lent G1322A degasser, G1311A quaternary pump, G1313A 
auto sampler, G1316A thermostat column compartment, 
and G1315B diode array detector (Agilent Technologies, 
USA). The software used to acquire and analyse the data was 
ChemStation® for LC 3D, Rev. A. 09.03 (Agilent Technolo-
gies, USA). Analysis was performed with a Luna® Omega 
5 μm PS  C18 150 × 4.60 mm column (Phenomenex, UK) 
equipped with a universal HPLC guard column (Phenom-
enex, UK) packed with a SecurityGuard™  C18 cartridge 
(Phenomenex, UK). For the analysis of amitriptyline, ace-
tonitrile and 0.1% TFA aqueous solution were selected as 
the mobile phase and gradient conditions were applied. The 
concentration of acetonitrile increased from 30 to 75% over 
14 min. The mobile phase was then returned to the initial 
proportion (30:70 0.1% TFA: acetonitrile) within 0.5 min 
and hold for 5 min to ensure system equilibrium before next 
injection. A flow rate of 1 mL/min was used. The column 
temperature and injection volume were set to 25 °C and 10 
μL, respectively. The wavelength used for the analysis of 
amitriptyline was 238 nm.
LC-MS was used to identify the degradation products of ami-
triptyline during the stability studies. The LC-MS system used 
in the study consisted of an Agilent G1322A degasser, G7111B 
quaternary pump, G7129A auto sampler, G1316A thermostat 
column compartment G7114A VWD detector coupled with 
G6135C single quadrupole mass spectrometer (Agilent Tech-
nologies, UK). The software used to acquire and analyse the 
data was OpenLAB CDS ChemStation® software (Agilent 
Technologies, UK). The analysis was performed using a Luna® 
Omega 5 μm PS  C18 150 × 4.60 mm column (Phenomenex, UK) 
equipped with a universal HPLC guard column (Phenomenex, 
UK) packed with a SecurityGuard™ C18 cartridge (Phenom-
enex, UK). An ion-spray voltage of 10 kV was applied, and the 
desolvation temperature was set to 350 °C. Nitrogen was used 
as the curtain gas (35 psi) and collision gas. The spectra were 
scanned in the positive ion peak over the m/z range of 100–750. 
For the chromatographic conditions, the mobile phase consisted 
of LC-MS grade 0.1% TFA aqueous solution and acetonitrile. 
The concentration of acetonitrile increased from 30 to 75% over 
16 min and then returned to starting conditions within 0.5 min. 
The mobile phase proportion was kept at 30:70 0.1% TFA: ace-
tonitrile for 5 min before next injection. A flow rate of 1 mL/min 
was used. The column temperature and injection volume were 
set to 25 °C and 10 μL, respectively. The wavelength used for 
UV detection was 238 nm.
Solubility parameter, solubility, and distribution 
coefficient determination
The solubility parameters (δ) of several solvents were cal-
culated by means of the van Krevelen and Hoftyzer type 
3-D approach [27] using Molecular Modelling Pro® Version 
6.3.3 software (ChemSW, Fairfield, CA, USA). For solubil-
ity measurements, an excess amount of amitriptyline free 
base or amitriptyline hydrochloride was added to 0.5 mL 
of each solvent in Eppendorf® tubes (n = 3). These Eppen-
dorf® tubes were sealed with Parafilm® and placed on a 
rotator at 32 ± 2 °C for at least 48 h. These samples were 
then centrifuged at 12,000 rpm for 15 min at 32 ± 1 °C. The 
supernatant was suitably diluted with methanol and ana-
lysed using the validated HPLC method (method validation 
parameters are shown in Table S1).
The method used for logarithm of distribution coefficient 
(Log D) measurement was the shake flask method, adapted 
from published OECD guidelines [28]. About 0.2 M sodium 
phosphate buffer solutions at pH = 6, 6.5, 7, and 7.4 were 
prepared and mutually saturated with 1-octanol by slow-
stirring (at 130 rpm) for 48 h at 25 °C. The solutions were 
equilibrated in a separating funnel for 24 h before separation. 
Amitriptyline solutions at 0.1 and 0.5 mmol/L were prepared 
in the 1-octanol phase. The solutions were mixed with the 
aqueous phase (sodium phosphate buffers) at three differ-
ent ratios (1:1, 2:1, and 1:2) in Eppendorf® tubes (n = 3). 
To reach equilibrium, these Eppendorf® tubes were rotated 
gently approximately one hundred times through 180° at 
room temperature, allowing the trapped air to rise through 
the two phases. Before sampling, tubes were then centri-
fuged at room temperature and at 13,000 rpm for 30 min so 
that the two phases separated from each other. Samples were 
taken from each phase with suitable dilution using methanol 
before HPLC analysis.
Stability studies
The chemical stability studies of amitriptyline in neat sol-
vents and in the Franz cell receptor medium were conducted 
for 96 h. A known quantity of amitriptyline was dissolved in 
the receptor medium or neat solvent. These solutions were 
placed in Eppendorf® tubes and sealed with Parafilm® 
before being placed in a shaker (VWR, UK) at 32 ± 1 °C. 
Samples were taken at 0, 24, 48, 72, and 96 h. The samples 
were diluted with methanol where necessary and analysed 
using HPLC or LC-MS.
Preparation of porcine skin
Porcine tissue was obtained from a local abattoir and pre-
pared on the day of slaughter. The porcine ear skin was 
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separated from cartilage at room temperature. Firstly, por-
cine tissue was washed with distilled water to remove dirt 
from the skin surface. Next, the superficial hair was trimmed 
with special care to avoid damage to the skin barrier. The 
skin was then separated slowly with the help of a scalpel and 
tweezers. After separation, the membrane was washed with 
distilled water and excess water was removed using tissue 
paper. Finally, the porcine tissue was stored in the freezer 
(− 30 °C) until required. Before a permeation study, frozen 
porcine skin was rapidly cut into discs using a cork-borer. 
The membrane was cleaned with HPLC grade water and 
blotted dry with filter paper before use.
In vitro permeation studies
In vitro permeation studies in full-thickness porcine skin 
were conducted according to OECD guideline no. 428 [29]. 
The skin integrity was assessed by measuring impedance 
at a frequency of 50 Hz before applying formulations [30]. 
The skin was considered intact if the impedance reading was 
above 15 kΩ at 50 Hz. Diffusion cells with an impedance 
value < 15 kΩ were discarded. Custom-made vertical glass 
Franz diffusion cells with a diffusion area of 1  cm2 were 
used. The assembled Franz cells were filled with 2.2 mL 
of degassed receptor medium (PBS pH 7.4 with 6% (w/v) 
Brij™ O20 and 0.05% (w/v) dithiothreitol). About 7-mm 
Teflon®-coated magnetic stir bars were then added into 
the receptor compartment, and all Franz cells were left in 
a thermostatted water bath at 34.5 ± 1 °C (SUB Aqua 26 
Plus, Grant, UK) for at least 30 min with stirring to ensure 
the membrane surface temperature was 32 ± 1 °C. After the 
equilibration period, a finite dose (5 μL/cm2) of 4% w/v 
amitriptyline formulation was applied evenly to the mem-
brane surface. 200-μL aliquots were withdrawn from 
the receptor compartment and replaced with fresh receptor 
medium at 0, 2, 4, 6, 8, 10, 12, and 24 h. All samples were 
analysed to quantify the amount of amitriptyline permeated 
using the validated HPLC method.
Mass balance studies
Mass balance studies were performed after each permeation 
study. The skin surface was washed three times with 1 mL 
of methanol. The skin was then placed in Eppendorf® tubes 
with 1 mL of methanol. The samples for skin extraction were 
placed in a shaker overnight to extract active ingredients. All 
Eppendorf ® tubes were centrifuged at 13,000 rpm at 32 °C 
for 15 min before sampling. The supernatant was sampled 
and diluted with methanol where necessary and analysed 
by HPLC.
Statistical analysis
Microsoft Excel® 2016 (Microsoft Corporation, USA) was 
used for data processing and the calculation of mean and 
standard deviation (SD). IBM® SPSS Statistics® 24.0 was 
used for statistical analysis. The Shapiro–Wilk test was used 
to assess the normality of the data. If the p value calculated 
from the test was higher than 0.05, the data were assumed to 
be normally distributed. For normally distributed data (para-
metric data), the independent-samples t test and one-way 
analysis of variance (ANOVA) with Tukey’s HSD post hoc 
test were used to analyse 2 groups and ≥ 3 groups respec-
tively. For non-normally distributed data (non-parametric 
data), the Mann–Whitney U test was used to test statistical 
significance between two groups and the Kruskal–Wallis 
one-way ANOVA test was performed to investigate statisti-
cal differences among different groups (≥ 3 groups). A prob-
ability of p < 0.05 was considered as a statistically significant 
difference.
Results and discussion
Preparation and characterization of amitriptyline 
free base
Successful conversion of amitriptyline hydrochloride to the 
free base was confirmed by 1H NMR (Fig. S1). A peak at 
5.3 ppm was assigned to dichloromethane, the residual sol-
vent. The Log p value of amitriptyline was reported as 4.92 
by Hansch et al. [31]. However, the experimental Log D 
values at pH 6–7.4 have not been reported. Therefore, Log D 
values of amitriptyline were measured at different pH values, 
and the results are listed in Table 1. The Log D value of ami-
triptyline increased with increasing pH values. The Log D 
value obtained at pH 7.4 for amitriptyline was 2.28 ± 0.02. 
The predicted log D value at pH 7.4 from ACD/Labs is 2.96.
Solubility and stability of amitriptyline
The solubility of amitriptyline free base and its hydrochloride 
salt in several common solvents for dermal delivery were 
Table 1  Distribution coefficient 
of amitriptyline base at different 
pH values
*Mean ± SD (n = 18)
pH Log D*
6.00 1.36 ± 0.01
6.50 1.64 ± 0.02
7.00 2.07 ± 0.03
7.40 2.28 ± 0.02
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assessed and the results are summarized in Table S2. Ami-
triptyline shows excellent solubility not only in hydrophobic 
solvents but also in some hydrophilic solvents such as PG and 
TC. As expected, amitriptyline hydrochloride showed high 
solubility only in polar solvents such as PG and TC.
To quantify accurately the amount of amitriptyline, the 
chemical stability of amitriptyline in the receptor medium 
was assessed. Therefore, stability studies for amitriptyline 
free base were conducted in the receptor medium. About 
6% w/v Brij™ O20 was added to the receptor medium to 
ensure sink conditions were maintained for amitriptyline 
during in vitro permeation studies (solubility of amitrip-
tyline base in 6% w/v Brij™ O20 was 14.15 ± 0.04 mg/mL 
at 32 ± 1 °C). During the stability studies of amitriptyline 
Fig. 1  LC-MS analysis of amitriptyline hydrochloride in pH 7.4 PBS + 6% Brij™ O20 at 32 ± 1 °C after 96 h. (a) A degradation product peak of 
amitriptline was observed. (b) The mass spectrum of the degradation product
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in pH 7.4 PBS (with 6% Brij™ O20), an unknown peak 
appeared, and the area of this peak increased with time, 
while the area of the peak of amitriptyline decreased with 
time (Fig. 1; Table 2). The recovery of amitriptyline in 
PBS with or without Brij™ O20 was ~ 75% at 24 h.
To investigate further the degradation of amitriptyline 
in PBS, LC-MS was used to analyse the amitriptyline deg-
radation product. This peak at 5.6 min is assigned to the 
amitriptyline degradation product which eluted slightly 
later than amitriptyline (Fig. 1). Mass spectrometry data 
suggest that the degradation product is likely to be a 
dimer of oxidized amitriptyline (m/z 586.9 for [M +  H]+). 
Although the single oxidized amitriptyline monomer (m/z 
293.9 for [M +  H]+) is expected to be more polar than ami-
triptyline, the dimer of oxidized amitriptyline might be 
expected to be more hydrophobic. This is consistent with 
the slightly longer retention time of the oxidation product 
of amitriptyline compared with amitriptyline.
To reduce the loss of amitriptyline in the receptor medium, 
one approach would be to add an antioxidant. Different con-
centrations of DTT (0.1%, 0.05%) were therefore added to 
6% Brij™ O20 pH 7.4 PBS to examine stabilization of ami-
triptyline. The effect of pH on the oxidation process of ami-
triptyline was also evaluated during the stability studies. The 
results are shown in Fig. 2. The oxidation rate of amitripty-
line in PBS was observed to be pH dependent following the 
order pH 6.5 < pH 7.0 < pH 7.4. Amitriptyline is stable over 
96 h after addition of 0.05% (w/v) DTT to pH 7.4 PBS with 
6% (w/v) Brij™ O20. Therefore, when 0.05% (w/v) DTT is 
added to the receptor medium, it should reduce the amount of 
oxidized amitriptyline during permeation studies compared 
with studies conducted with no antioxidant in the receptor 
medium. In addition, no adverse effect on skin barrier was 
detected by impedance assessment when 0.05% (w/v) DTT 
and 6% (w/v) Brij™ O20 were added to the receptor medium 
(Fig. S2).
The stability of amitriptyline free base in neat TC, IPM, 
PG, PGML, OSAL, IPA, and EtAc was also assessed. 
The results are shown in Fig. 3. The recovery values in all 
these solvents were above 95%. The chemical stability of 
amitriptyline free base in these solvents at 32 ± 1 °C (over 
96 h) was therefore confirmed. IPM and PG which show 
contrasting physicochemical properties and favourable solu-
bility of amitriptyline free base (Table S2) were selected as 
the model solvents take forward in combination with IPA.
The influence of IPM/IPA binary systems
IPM is commonly used in pharmaceutical and cosmetic for-
mulations [32]. IPA is a volatile solvent with a vapour pres-
sure value of 4.4 kPa at 20 °C [33]. It has also been used in 
a number of topical products, and it is considered safe for 
application to the skin [34]. The effects of the combined use 
of IPM and IPA on amitriptyline permeation were studied 
under finite dose conditions. The permeation profiles of ami-
triptyline from IPM/IPA binary formulations are shown in 
Fig. 4. The highest cumulative amount of amitriptyline that 
permeated through porcine skin at 24 h was observed for 
IPM:IPA (5:95) (one-way ANOVA, p < 0.01), followed by 
IPM:IPA (25:75). There were 8.0-fold and 5.4-fold increases 
in the amount of amitriptyline that permeated at 24 h for 
IPM:IPA (5:95) and IPM:IPA (25:75), respectively, com-
pared with neat IPM. This indicates that the high concen-
tration of IPA in IPM/IPA binary formulations contribute 
greatly to an increased skin permeation. The increase in 
thermodynamic activity of amitriptyline base after the rapid 
evaporation of IPA may facilitate the partition of amitripty-
line from IPM into the stratum corneum.
The mass balance results for the IPM/IPA binary sys-
tems are shown in Fig. 5. For the IPM/IPA binary systems 
33.0–41.1% of the applied amitriptyline dose was recovered 
from the skin. This indicates that skin may serve as a reser-
voir for amitriptyline. The hydrophilic nature of the dermal 
layer can also be a barrier for the diffusion of amitriptyline, a 
highly lipophilic compound [35]. The permeation of amitrip-
tyline increased with the concentration of IPA in IPM/IPA 
binary formulations, while the percentage of amitriptyline 
remaining on the skin surface decreased with the increasing 
concentration of IPA. This indicates that the presence of 
IPA plays a key role in enhancing the skin permeation of 
amitriptyline. The IPM:IPA (5:95) formulation delivered a 
significantly higher (one-way ANOVA, p < 0.01) percentage 
of applied amitriptyline through porcine skin compared with 
the other IPM/IPA binary formulations. Only 14.52 ± 1.53% 
of applied amitriptyline from the IPM:IPA (5:95) formu-
lation remained on the skin surface after 24 h. Therefore, 
IPM:IPA (5:95) may be a promising formulation for the 
delivery of amitriptyline base.
Sato et al. [36] suggested that IPM may affect the dif-
fusivity of actives in the stratum corneum and increase the 
partition of both drugs and solvents from vehicles into the 
stratum corneum. The integration of IPM with lipids of the 
stratum corneum may fluidize the lamellar-gel phase of 
Table 2  Recovery (%) of amitriptyline hydrochloride in pH 7.4 
PBS and 6% Brij™ O20 in pH 7.4 PBS after 24, 48, 72, and 96 h at 
32 ± 1 °C (n = 3; mean ± SD)
Solvents 6% Brij™ O20 in pH 7.4 
PBS
pH 7.4 PBS
T = 0 h 100.0 100.0
T = 24 h 75.5 ± 0.7 75.2 ± 0.6
T = 48 h 72.1 ± 0.7 71.4 ± 0.6
T = 72 h 71.5 ± 1.1 63.4 ± 0.2
T = 96 h 65.9 ± 0.8 57.5 ± 0.3
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the lipids [37]. Oliveira et al. [38] conducted methyl para-
ben permeation studies and evaluated the human stratum 
corneum uptake of solvents, including IPM. The authors 
reported that the highest partition coefficient of methyl para-
ben was obtained from IPM compared with other solvents, 
including dimethyl isosorbide, Transcutol®, polyethylene 
glycol 200, and polyethylene glycol 400. Haque et al. [39] 
evaluated the distribution of a number of solvents for finite 
dose permeation studies of anthramycin. The results showed 
that IPM did not permeate through skin while ~ 10% of IPM 
was recovered following skin extraction.
The influence of PG/IPA binary systems.
The permeation profiles of amitriptyline for PG/IPA 
binary formulations are shown in Fig. 6. Although there 
were no significant differences (one-way ANOVA, p > 0.05) 
between the cumulative amounts of amitriptyline that per-
meated from PG/IPA systems at 24 h, all formulations deliv-
ered more than 70 μg/cm2 of amitriptyline through porcine 
skin. Unlike the IPM/IPA systems, the permeation of ami-
triptyline from PG/IPA systems did not increase with the 
concentration of IPA in the applied formulations.
Fig. 2  Recovery of amitripty-
line hydrochloride in different 
receptor phases after 24, 48, 
72, and 96 h at 32 ± 1 °C (n = 3; 
mean ± SD). The recovery of 
amitriptyline hydrochloride in 
pH 7.4 PBS with 0.05% DTT 
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pH 7 PBS pH 7.4 PBS
Fig. 3  Recovery (%) of ami-
triptyline free base in a series 
of neat solvents after 24, 48, 
72, and 96 h at 32 ± 1 °C (n = 3; 
mean ± SD). TC Transcutol®P, 
IPM isopropyl myristate, 
PG propylene glycol, PGML 
propylene glycol monolaurate, 
OSAL octyl salicylate, IPA 















T = 0 h T = 24 h T = 48 h T = 72 h T = 96 h
 Drug Delivery and Translational Research
1 3
The results of the mass balance studies for the PG/
IPA systems are shown in Fig. 7. In general, the highest 
percentages of applied amitriptyline were recovered from 
the receptor medium, followed by skin extraction, and 
from the skin surface. Only 11.8–22.8% of the applied 
amitriptyline remained on the skin surface at 24 h. This 
indicates that all PG/IPA binary formulations are prom-
ising vehicles for dermal delivery of amitriptyline base. 
The overall recoveries for all the formulations tested in 
the present study were > 80%.
In general, PG and PG/IPA binary systems delivered 
higher amounts of amitriptyline to the skin compared with 
IPM/IPA binary systems. Amitriptyline base is a thick oil 
at room temperature with a molecular weight of 277 Da. 
The solubility parameter of amitriptyline base is 10.54 (cal/
cm3)1/2 which is close to the reported solubility parameters 
Fig. 5  Percentages of amitrip-
tyline recovered from the skin 
surface, skin extraction, and 
following skin permeation after 
24-h permeation studies in 
porcine skin. Finite doses (5 μL/
cm2) of 4% (w/v) amitriptyline 
base in IPM, IPM:IPA (75:25), 
IPM:IPA (50:50), IPM:IPA 
(25:75), and IPM:IPA (5:95) 
were applied in permeation 
studies (mean ± SD; 4 ≤ n ≤ 5). 
IPM isopropyl myristate, IPA 
isopropyl alcohol. Statistical 
differences were obtained using 
one-way ANOVA followed 
by Tukey’s multiple com-
parisons test where appropriate, 
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**
Fig. 4  Permeation profiles of 
amitriptyline in porcine ear 
skin after application of 4% 
(w/v) amitriptyline base in IPM 
(blue circle), IPM:IPA (75:25) 
(orange square), IPM:IPA 
(50:50) (gray triangle), 
IPM:IPA (25:75) (yellow cross 
sign), and IPM:IPA (5:95) (light 
blue) for finite dose (5 μL/
cm2) conditions at 32 ± 1 °C 
(mean ± SD; 4 ≤ n ≤ 5). IPM iso-
propyl myristate, IPA isopropyl 
alcohol. Statistical differences 
were obtained using one-way 
ANOVA followed by Tukey’s 
multiple comparisons test 
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of stratum corneum lipids (9.7–10 (cal/cm3)1/2) [40]. This 
indicates amitriptyline base should have favourable solubil-
ity in stratum corneum lipids. Amitriptyline base has high 
solubility (> 1000 mg/mL) in PG at 32 ± 1 °C (Table S2). 
The uptake of PG into skin may increase further the solu-
bility of amitriptyline in the skin and promote the partition 
of amitriptyline into the skin. A number of studies have 
investigated the effects of PG on skin permeation of actives 
[41–51]. The skin permeation of both metronidazole and 
PG from various formulations containing PG have been 
reported. The results showed that the permeation of met-
ronidazole increased with the degree of PG permeation. 
Therefore, the authors suggested that PG may enhance met-
ronidazole permeation by acting as a “carrier solvent” [49]. 
Kasting et al. [45] conducted in vitro permeation studies in 
human skin under infinite dose conditions (150 μL per 0.79 
 cm2). The results showed that PG enhanced the skin permea-
tion of triprolidine base compared with lipophilic solvents 
Fig. 6  Permeation profiles of 
amitriptyline in porcine ear 
skin after application of 4% 
(w/v) amitriptyline base in PG 
(blue circle), PG:IPA (75:25) 
(orange square), PG:IPA 
(50:50) (gray triangle), PG:IPA 
(25:75) (yellow cross sign), 
and PG:IPA (5:95) (light blue 
circle) for finite dose (5 μL/
cm2) conditions at 32 ± 1 °C 
(mean ± SD; 4 ≤ n ≤ 5). IPM iso-
propyl myristate, IPA isopropyl 
alcohol. Statistical differences 
were obtained using one-way 
ANOVA followed by Tukey’s 
multiple comparisons test 





































PG PG:IPA (75:25) PG:IPA (50:50) PG:IPA (25:75) PG:IPA (5:95)
Fig. 7  Percentages of amitrip-
tyline recovered from the skin 
surface, skin extraction, and 
following skin permeation after 
24-h permeation studies in 
porcine skin. Finite doses (5 μL/
cm2) of 4% (w/v) amitriptyline 
base in PG, PG:IPA (75:25), 
PG:IPA (50:50), PG:IPA 
(25:75), and PG:IPA (5:95) 
were applied in permeation 
studies (mean ± SD; 4 ≤ n ≤ 5). 
IPM isopropyl myristate, IPA 
isopropyl alcohol. Statistical 
differences were obtained using 
one-way ANOVA followed 
by Tukey’s multiple com-
parisons test where appropriate, 
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such as IPM and mineral oil. The authors suggested that PG 
was incorporated into the stratum corneum and modified 
the solubility of the permeant in stratum corneum. Trottet 
et al. [47] reported the skin permeation of loperamide and 
PG in human skin. Loperamide hydrochloride formulations 
with 12–40% PG were assessed under finite dose conditions 
(10 mg/cm2). The results showed that the fluxes of both lop-
eramide and PG through human skin were proportional to 
the applied doses of propylene glycol. More recently, Haque 
et al. [39] conducted finite dose permeation studies of anth-
ramycin in human skin and reported the skin uptake of vehi-
cles such as PG and TC. The authors confirmed that the 
majority of PG applied permeated through the skin rather 
than remaining on the skin surface.
Conclusion
Amitriptyline is currently given orally for the management 
of neuropathic pain and migraine. The molecule has favour-
able propeties for demal delivery but few studies have exam-
ined the skin permeation of amitriptyline. The present work 
demonstrated effective skin penetration of amitriptyline 
from a range of vehicles based on IPA, PG and IPM. For 
permeation studies, the instability of amitriptyline in PBS 
was overcome by inclusion of a suitable additive, namely, 
0.05% (w/v) DTT. The maximum cumulative amounts of the 
drug that permeated were obtained with PG, PG/IPA binary 
systems and IPM:IPA (5:95), without significant differences 
among these systems. About 72–96 μg/cm2 of amitriptyline 
can be delivered through skin at 24 h under finite dose con-
ditions. Future work will focus on further optimization of 
these preparations and evaluation in human skin permeation 
studies with a view to progressing them towards develop-
ment in the clinic.
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